Type in a keyword and see the report right away. Explore your online world!
If you have already a Newsmeter account:
You can free sign up for Newsmeter:
x
UMB Bank n. a. lifted its stake in Bristol-Myers Squibb ( NYSE: BMY – Free Report ) by 52. 6% in the 1st quarter, Holdings Channel reports. The firm owned 313, 433 shares of the biopharmaceutical comp...
06.07.2025 Techdows.com and 102 sites
Key Points AbbVie is a Dividend King with a strong product lineup. Bristol Myers Squibb offers a high dividend yield and has underrated growth potential. Pfizer's dividend and underlying business are ...
06.08.2025 Yahoo.com and 1 sites
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansi...
06.09.2025 Yahoo.com
Mogy Joel R Investment Counsel Inc. trimmed its holdings in Bristol-Myers Squibb ( NYSE: BMY – Free Report ) by 1. 1% during the first quarter, according to the company in its most recent filing with ...
06.10.2025 Thestockobserver.com and 61 sites
Consideration composed of a $350m up-front payment and up to $1. 0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ('Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL: PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Ph...
06.10.2025 Centralcharts.com and 14 sites
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks are higher t...
06.09.2025 Cnbc.com
Head and Neck Cancer Drugs Market Insights Head and Neck Cancer Drugs Market is estimated to be valued at USD 2, 286. 6 Mn in 2025 and is expected to reach USD 3, 744. 5 Mn in 2032, exhibiting a compo...
06.09.2025 Openpr.com and 77 sites
Today, positive late-breaking results from the pivotal phase 3 POETYK PsA-1 (NCT04908202) and POETYK PsA-2 (NCT04908189) trials were released, showing that deucravacitinib (Sotyktu; Bristol Myers Squi...
06.11.2025 Centralcharts.com and 6 sites
WALTHAM, Mass. , June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies f...
06.10.2025 Globenewswire.com and 20 sites
2025 Market Reports Update: Forecasts Through 2034, Emerging Trends, Key Players, and Leading Regions – Stay Ahead of the Competition Today! We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shift...
06.11.2025 Whatech.com and 14 sites
